Author name: Rose Wango

Policies Regarding the Use of Illicit Substances

A 23-year-old woman attends an outpatient treatment program and office-based buprenorphine clinic. She has been doing well while maintained on 16 mg/day of buprenorphine. Recently though, she has missed group sessions and provided a urine for drug screening that tested positive for clonazepam and amphetamine. One of the other members in her group reported that they

Policies Regarding the Use of Illicit Substances Read More »

Policies Regarding Urine Adulteration/Substitution

A 23-year-old woman attends an outpatient treatment program and office-based buprenorphine clinic. She has been doing well while maintained on 16 mg/day of buprenorphine. Recently though, she has missed group sessions and provided a urine for drug screening that tested positive for clonazepam and amphetamine. One of the other members in her group reported that they

Policies Regarding Urine Adulteration/Substitution Read More »

Pain Management in Patients on Buprenorphine-Naloxone

A 27-year-old woman on buprenorphine-naloxone (Suboxone®) for treatment of opioid dependence is admitted to the hospital with severe abdominal pain due to a perforated gastric ulcer. She received hydromorphone in the ED, and is urgently taken to the operating room. Postoperatively, she is on a patient-controlled analgesic (PCA) pump containing fentanyl. Her last dose of

Pain Management in Patients on Buprenorphine-Naloxone Read More »

error: Content is protected !!
Scroll to Top